Advertisement
Document › Details
Medigene AG. (1/17/19). "Press Release: Medigene Participates at Four Upcoming Conferences". Martinsried.
Organisation | Medigene AG (FSE: MDG1, Prime Standard) | |
Group | Medigene (Group) | |
Product | TCR engineered T-cells | |
Product 2 | cancer immunotherapy (immuno-oncology, I-O) | |
Martinsried/Munich - Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming investor and scientific conferences:
Harald von Boehmer Midwinter Conference 2019 International Immunobiology Symposium
Date: 19 - 23 January 2019
Location: Seefeld in Tirol, Austria
Guggenheim Healthcare Talks/Oncology Day
Date: 14 February 2019
Location: New York, USA
13th ODDO BHF German Conference
Date: 19 - 20 Februar 2019
Location: Frankfurt, Germany
CAR-TCR Summit Europe 2019
Date: 25 - 27 Februar 2019
Location: London, UK
Prof. Dolores Schendel, CEO and CSO of Medigene, will give a presentation on 26 February entitled "Next generation TCR-T cell therapies can offer improved safety and enhanced efficacy" and Dr. med. Kai Pinkernell, CMO and CDO of Medigene will talk about "Obtaining clinical trial authorisation for TCR-modified T cells in Germany" on 27 February.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact
Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com
Record changed: 2023-06-05 |
Advertisement
More documents for Medigene (Group)
- [1] Medigene AG. (2/25/22). "Press Release: Dr. Selwyn Ho Appointed New CEO of Medigene". Lisbon....
- [2] Medigene AG. (2/11/19). "Press Release: Medigene Appoints Axel-Sven Malkomes as CFO/CBDO". Martinsried....
- [3] Medigene AG. (4/28/17). "Press Release: Medigene Announces Participation at Six International Conferences". Planegg....
- [4] Medigene AG. (2/2/17). "Press Release: Medigene Participates at Five National and International Conferences in February and March 2017". Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top